Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat TQT Study in Healthy Adults
NCT04607512Phase 1Completed
- Sponsor
- Calithera Biosciences
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of telaglenastat in solid tumor and renal cell carcinoma (RCC) (3 arms), sponsored by Calithera Biosciences. Primary endpoint: Change in QTcF Interval at Day 4. Started Oct 2020; status: completed.
02
Drugs
telaglenastat
03
Conditions
solid tumorrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04607512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04607512.